Clinical Trial Update: Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial [Phase 2]

View source ↗

Summary

This is a Phase II, multi-center randomized trial protocol evaluating neoadjuvant moderately hypofractionated radiotherapy with chemotherapy and the PD-1 inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Fudan University | Conditions: Rectal Cancer, Moderately Hypofractionated Radiotherapy | Phase 2 | Status: NOT_YET_RECRUITING